Also, the treatment guidelines for T2DM subclassify treatment of T2DM with HF in a different way (prioritizing sodium-dependent glucose cotransporter 2 [SGLT-2] inhibitors and glucagon-like peptide 1 [GLP-1] receptor agonists over other medications) as compared to those without T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.